[{"id":"8c3bb79a-38ec-407f-9a3b-e0b7f0e87734","acronym":"SIRIUS-SLE 1","url":"https://clinicaltrials.gov/study/NCT05639114","created_at":"2022-12-06T15:58:04.147Z","updated_at":"2025-02-25T16:54:35.553Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)","source_id_and_acronym":"NCT05639114 - SIRIUS-SLE 1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CTLA4 • IFNAR2","pipe":"","alterations":" ","tags":["CTLA4 • IFNAR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ianalumab (VAY736)"],"overall_status":"Recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 01/19/2027","primary_completion_date":" 01/19/2027","study_txt":" Completion: 04/20/2029","study_completion_date":" 04/20/2029","last_update_posted":"2025-02-04"},{"id":"bdf42d2c-bdaa-4f71-bfd4-c8873f63c108","acronym":"SIRIUS-SLE 2","url":"https://clinicaltrials.gov/study/NCT05624749","created_at":"2022-11-22T15:58:58.720Z","updated_at":"2024-07-02T16:34:26.748Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)","source_id_and_acronym":"NCT05624749 - SIRIUS-SLE 2","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CTLA4 • IFNAR2","pipe":"","alterations":" ","tags":["CTLA4 • IFNAR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ianalumab (VAY736)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/21/2023","start_date":" 04/21/2023","primary_txt":" Primary completion: 01/26/2027","primary_completion_date":" 01/26/2027","study_txt":" Completion: 01/23/2029","study_completion_date":" 01/23/2029","last_update_posted":"2024-06-12"}]